| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We isolated cancer-associated fibroblast and normal fibroblast from advanced gastric cancer tissue. VEGF isoform and CCL2, which were secreted from fibroblasts, were concerned with a clinical course of gastric cancer patients. We performed a clinical study (UMIN 000017123) for relapsed or metastatic gastric cancer patients. It became clear that CCL2/CCR2 axis inhibition by Propagermanium improved overall survival to participate in immunopotentiative effects and tumor dormancy.
|
